Basel-based Lonza joined CMAC, a center for medicines manufacturing research, to enhance its service offering for particle technologies and drug product development and manufacture.
Based at the University of Strathclyde in Glasgow, Scotland, CMAC is an international research hub with a configuration of academic and industrial companies within applied and pre-competitive research programs, and translation to industry models. It aims to transform pharmaceutical manufacturing and crystallization processes by developing continuous manufacturing technologies, optimizing efficiency, and enhancing product quality.
Lonza will now gain access to CMAC’s network, which advances chemistry, manufacturing, and control (CMC) technologies, implements digitalization strategies, and develops continuous processing and crystallization solutions for active pharmaceutical ingredients and drug product technologies. Lonza’s participation in CMAC will ensure the effective application of research outcomes to strengthen CMC processes and their implementation for its customers, according to Francois Ricard, PhD, head of R&D, advanced synthesis, Lonza.
“Our participation in CMAC will allow us to work with world-leading industry and academia experts and apply best practices in the fields of API development, continuous processing, drug product development, and overall digital CMC strategy,” said Ricard. “Our global team will drive the implementation of these processes and technologies across scales in a CDMO setup for the benefit of our customers and partners.”
‘‘Welcoming Lonza into CMAC marks a significant milestone in our mission to transform medicines manufacturing. Its global leadership, technical depth, and strategic vision will be instrumental in shaping and accelerating the adoption of highly automated manufacturing platforms and advanced CMC solutions,” added Massimo Bresciani, CMAC, industry director. “This collaboration reinforces our commitment to building a connected ecosystem where academic innovation and industrialists converge to translate cutting-edge research into impactful, scalable solutions for the pharmaceutical and biotech sectors.’’
The post Lonza Joins Center for Continuous Manufacturing and Advanced Crystallization appeared first on GEN - Genetic Engineering and Biotechnology News.
Based at the University of Strathclyde in Glasgow, Scotland, CMAC is an international research hub with a configuration of academic and industrial companies within applied and pre-competitive research programs, and translation to industry models. It aims to transform pharmaceutical manufacturing and crystallization processes by developing continuous manufacturing technologies, optimizing efficiency, and enhancing product quality.
Lonza will now gain access to CMAC’s network, which advances chemistry, manufacturing, and control (CMC) technologies, implements digitalization strategies, and develops continuous processing and crystallization solutions for active pharmaceutical ingredients and drug product technologies. Lonza’s participation in CMAC will ensure the effective application of research outcomes to strengthen CMC processes and their implementation for its customers, according to Francois Ricard, PhD, head of R&D, advanced synthesis, Lonza.
“Our participation in CMAC will allow us to work with world-leading industry and academia experts and apply best practices in the fields of API development, continuous processing, drug product development, and overall digital CMC strategy,” said Ricard. “Our global team will drive the implementation of these processes and technologies across scales in a CDMO setup for the benefit of our customers and partners.”
‘‘Welcoming Lonza into CMAC marks a significant milestone in our mission to transform medicines manufacturing. Its global leadership, technical depth, and strategic vision will be instrumental in shaping and accelerating the adoption of highly automated manufacturing platforms and advanced CMC solutions,” added Massimo Bresciani, CMAC, industry director. “This collaboration reinforces our commitment to building a connected ecosystem where academic innovation and industrialists converge to translate cutting-edge research into impactful, scalable solutions for the pharmaceutical and biotech sectors.’’
The post Lonza Joins Center for Continuous Manufacturing and Advanced Crystallization appeared first on GEN - Genetic Engineering and Biotechnology News.